Want to see RNA full AI Analyst Report?
RNA Stock Chart & Stats
$13.64
-$0.39(-1.27%)
At close: 4:00 PM EST
$13.64
-$0.39(-1.27%)
Day’s Range― - ―
52-Week Range$11.13 - $16.77
Previous CloseN/A
Volume185.29K
Average Volume (3M)139.10K
Market Cap
$240.51M
Enterprise Value-$32.45
Total Cash (Recent Filing)$264.21M
Total Debt (Recent Filing)$1.68M
Price to Earnings (P/E)―
Beta1.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,105,642
10 Day Avg. Volume175,087
30 Day Avg. Volume139,105
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.22
Price to Sales (P/S)13.56
P/FCF Ratio-5.93
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$25.00Price Target Upside83.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic BMS Partnership And Milestone EconomicsThe Bristol Myers Squibb collaboration provides non-dilutive milestone potential, royalty upside and validation from a major pharmaceutical partner. BMS funding future clinical, regulatory and commercialization work could materially reduce Atrium’s development burden.
Clinical Pipeline AdvancementFDA clearance and initiation of a Phase 1/2 study move Atrium’s precision cardiomyopathy programs into clinical development. This creates potential future value from differentiated RNA-based therapies and expands the company’s development-stage pipeline.
Very Low Financial LeverageMinimal debt reduces refinancing exposure, interest-related pressure and solvency risk while Atrium funds a lengthy biotechnology development cycle. Although the company remains cash-burning, low leverage preserves flexibility compared with highly indebted peers.
Bears Say
Persistent Cash Burn And Funding DependenceSustained operating and free-cash-flow deficits indicate that Atrium cannot currently fund development from internal operations. Continued reliance on external capital may create dilution or financing risk and could constrain investment if funding conditions deteriorate.
Deeply Negative ProfitabilityLarge net and operating losses show that Atrium remains in an intensive investment phase without an established profit engine. Negative returns on equity also indicate that current shareholder capital is not yet producing sustainable economic returns.
Small, Volatile And Declining Revenue BaseLimited and declining revenue provides little operating support for Atrium’s substantial research costs. Revenue volatility increases dependence on milestone receipts, partnerships or financing until clinical programs mature into recurring commercial products.
Atrium Therapeutics, Inc. News
RNA FAQ
What was Atrium Therapeutics, Inc.’s price range in the past 12 months?
Atrium Therapeutics, Inc. lowest stock price was $11.13 and its highest was $16.77 in the past 12 months.
What is Atrium Therapeutics, Inc.’s market cap?
Atrium Therapeutics, Inc.’s market cap is $240.51M.
When is Atrium Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Atrium Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Atrium Therapeutics, Inc. overvalued?
According to Wall Street analysts Atrium Therapeutics, Inc.’s price is currently Undervalued.
Does Atrium Therapeutics, Inc. pay dividends?
Atrium Therapeutics, Inc. does not currently pay dividends.
What is Atrium Therapeutics, Inc.’s EPS estimate?
Atrium Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atrium Therapeutics, Inc. have?
Atrium Therapeutics, Inc. has 17,105,642 shares outstanding.
What happened to Atrium Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atrium Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atrium Therapeutics, Inc. Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
RNA Stock 12 Month Forecast
Average Price Target
$25.00
▲(83.28% Upside)
Technical Analysis
Arcturus Therapeutics
―
Rocket Pharmaceuticals
―
Cartesian Therapeutics
―
Precision BioSciences
―
Entrada Therapeutics Inc
―
Ownership Overview
2.24% Insiders
1.51% Mutual Funds
37.04% Other Institutional Investors
49.86% Public Companies and
Individual Investors